Eli Lilly and Cipla have partnered to expand access to Tirzepatide (Yurpeak®) in India, marking a strategic move to address the country’s growing diabetes and obesity burden. Under this agreement, Lilly will handle manufacturing while Cipla leverages its extensive distribution network to enhance patient reach, especially in tier-2 and tier-3 cities.
Get More Insights on the topic -https://www.linkedin.com/feed/update/urn:li:activity:7387392185983238145/
Get More Insights on the topic -https://www.linkedin.com/feed/update/urn:li:activity:7387392185983238145/
Eli Lilly and Cipla have partnered to expand access to Tirzepatide (Yurpeak®) in India, marking a strategic move to address the country’s growing diabetes and obesity burden. Under this agreement, Lilly will handle manufacturing while Cipla leverages its extensive distribution network to enhance patient reach, especially in tier-2 and tier-3 cities.
Get More Insights on the topic -https://www.linkedin.com/feed/update/urn:li:activity:7387392185983238145/
0 Comments
0 Shares